No Data
Myriad Genetics Disputes Inclusion of GeneSight in UnitedHealthcare's Coverage Restriction
Myriad Genetics Was Informed On Friday, November 1, 2024, Of An Updated Medical Policy From UnitedHealthCare Restricting Access To Multi-Gene Panel Pharmacogenetic Tests, Including Myriad's Genesight Test, Under Its Commercial And Individual Exchange...
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Maintains Target Price $30
TD Cowen Reaffirms Their Hold Rating on Myriad Genetics (MYGN)
Benign Growth For Myriad Genetics, Inc. (NASDAQ:MYGN) Underpins Stock's 33% Plummet
Earnings Preview: MYGN to Report Financial Results Post-market on November 07
$Myriad Genetics(MYGN.US)$ is scheduled to release its financial results post-market on November 07 ET. Earnings PreviewAnalysts estimate $Myriad Genetics(MYGN.US)$ to post revenue of USD210.79M for 2
No Data
No Data